Company intelligence / Profile preview

Pan-Provincial Vaccine Enterprise

Saskatoon, Saskatchewan, Canada

Ownership: Private
Development stage: Other

Overview

PREVENT accelerated Canadian early-stage vaccine candidates to animal studies and proof-of-concept trials, with some projects advancing to human clinical testing; notable for collaboration on a multivalent group A streptococcus vaccine with Vaxent

Therapeutic areas: Infectious DiseasesRheumatologyCardiovascular
Modalities: VaccineProtein (specifically recombinant protein subunit vaccines)
Industry: Academic Hospital/University/Research

Partnerships

Vaxent (co-development of Group A Streptococcus vaccine)Vaccine and Infectious Disease Organization (VIDO/University of Saskatchewan)BC Centre for Disease Control (BC-CDC)Canadian Center for Vaccinology (CCfV)

Beyond the preview

Go deeper on Pan-Provincial Vaccine Enterprise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pan-Provincial Vaccine Enterprise.

Explore the full profile